Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 8.82B -27.7% |
| Revenue (ttm) | 4.77B +6.0% |
| Net Income | 480.47M +29.3% |
| EPS | 0.56 +31.8% |
| Shares Out | 841.19M |
| PE Ratio | 18.84 |
| Forward PE | 12.28 |
| Dividend | 0.29 (2.75%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 3,143,556 |
| Open | 1,028.50 |
| Previous Close | 1,008.50 |
| Day's Range | 1,026.50 - 1,056.00 |
| 52-Week Range | 1,008.50 - 1,426.60 |
| Beta | 0.68 |
| Analysts | Hold |
| Price Target | 1,257.02 (+19.89%) |
| Earnings Date | Nov 5, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,257p, which is an increase of 19.89% from the latest price.
News
Smith & Nephew price target raised to $33.88 from $33.77 at Berenberg
Berenberg raised the firm’s price target on Smith & Nephew to $33.88 from $33.77 and keeps a Hold rating on the shares.
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology ...
Smith & Nephew downgraded to Neutral from Buy at BofA
BofA downgraded Smith & Nephew to Neutral from Buy with a price target of 1,150 GBp, down from 1,340 GBp. FY26 sales growth guidance was lowered at Q2, notes the…
Smith & Nephew downgraded at Morgan Stanley on expected rebase
As previously reported, Morgan Stanley downgraded Smith & Nephew to Equal Weight from Overweight with a price target of 1,158 GBp, down from 1,304 GBp. The firm thinks Smith &…
Smith & Nephew downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Smith & Nephew to Equal Weight from Overweight with a price target of 1,158 GBp, down from 1,304 GBp.
Smith & Nephew initiated with a Neutral at BTIG
BTIG analyst Ryan Zimmerman initiated coverage of Smith & Nephew with a Neutral rating and no price target The company competes in an over $50B total addressable market and is…
Smith & Nephew price target lowered to 1,120 GBp from 1,300 GBp at UBS
UBS lowered the firm’s price target on Smith & Nephew to 1,120 GBp from 1,300 GBp and keeps a Neutral rating on the shares.
London's FTSE 100 slips after inflation report; Smith+Nephew drops
London shares edged lower on Wednesday as investors assessed an in-line inflation report, while Smith+Nephew fell after announcing the departure of its finance chief.
Smith & Nephew announces resignation of CFO John Rogers
Smith & Nephew announced that John Rogers informed the board of his intention to leave his position as Chief Financial Officer on September 30 to take up an external position…
UK's Smith+Nephew CFO John Rogers to step down for external role
Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure...
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
Marking a new approach to innovation in medical robotics, the new centre will bring advances from a leading surgical robotics research group to patients more quickly Smith+Nephew (LSE:SN, NYSE:SNN), t...
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
Smith+Nephew and Imperial College London have launched a five-year partnership to deliver research for robotic surgery for musculoskeletal conditions.
Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an exte...
Smith & Nephew SNATS Q2 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN reported second-quarter underlying revenue growth of 1.6%, below management's expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U....
Smith & Nephew price target lowered to 1,250 GBp from 1,350 GBp at RBC Capital
RBC Capital lowered the firm’s price target on Smith & Nephew to 1,250 GBp from 1,350 GBp and keeps a Sector Perform rating on the shares.
Smith & Nephew price target lowered to 1,250 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Smith & Nephew to 1,250 GBp from 1,400 GBp and keeps a Hold rating on the shares.
Smith & Nephew downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Smith & Nephew to Neutral from Overweight with a price target of 1,290 GBp, down from 1,438 GBp. The company is seeing a “material and broad” slowdown, the…
Smith & Nephew price target lowered to 1,304 GBp at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Smith & Nephew to 1,304 GBp from 1,333 GBp and keeps an Overweight rating on the shares. Published first…
Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week
Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration wi...
Smith & Nephew downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Smith & Nephew to Underweight from Equal Weight with a price target of 1,050 GBp, down from 1,290 GBp. The firm views the company’s Q2 as worse than…
Smith & Nephew Earnings Call Transcript: Q2 2026
Q2 revenue growth was below expectations at 1.6%, with strong Sports Medicine and ENT offset by U.S. Orthopaedics and Advanced Wound Bioactives softness. Profitability remained robust, supported by efficiency savings and tariff refunds, and full-year profit guidance is maintained despite a reduced revenue outlook.
Smith & Nephew Quarterly report: Q2 2026
Smith & Nephew has published its Q2 2026 quarterly earnings report on August 4, 2026.
Smith & Nephew Slides: Q2 2026
Smith & Nephew has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
UK's Smith+Nephew cuts annual revenue expectations
British medical products company Smith+Nephew cut its full-year revenue growth forecast on Tuesday, as continued weakness in its orthopaedics unit in the U.S, its largest market, weighed ...